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The International Federation of Gynecologists and
Obstetricians (FIGO) has recently revised the staging of
ovarian cancer [1]. It includes a revision of the stage III
patients and allotment to stage IIIA1 is based on spread
to the retroperitoneal lymph nodes without intraperito-
neal dissemination, because an analysis of these patients
indicates that their survival is significantly better than
those who have intraperitoneal dissemination [1]. The
FIGO staging system for ovarian cancer is surgically
based. It does not formally include imaging but the
FIGO committee encourages the use of imaging techni-
ques if available to assess the important prognostic fac-
tors such as disease resectability and lymph node status.
The standard of care for patients with newly diag-
nosed advanced ovarian cancer has been comprehensive
staging laparotomy and primary optimal surgical cytore-
duction followed by adjuvant chemotherapy. However,
the use of neoadjuvant chemotherapy followed by inter-
val debulking surgery (IDS) as a suitable alternative is
supported by multicenter randomized controlled trials
[2]. Imaging is therefore of paramount importance in
helping triage patients for appropriate management by
accurately evaluating the extent and anatomical location
of peritoneal spread, which in turn dictates the feasibil-
ity of cytoreductive surgery and predicts the likelihood
of optimal primary cytoreduction. Optimal cytoreductive
surgery (residual disease <1 cm) is a very strong predic-
tor of survival, and even after the threshold for optimal
cytoreduction has been reached, it is important to
remove as much of the residual tumor as possible.
CT is the primary imaging modality used to stage ovar-
ian cancer. It is complimentary to surgical staging identify-
ing possible sites of unsuspected disease such as pelvic
peritoneum, paraaortic nodes, diaphragm and chest [3,4].
The thorax frequently harbors undiagnosed pleural disease
at the time of the initial diagnosis which is likely to affect
survival even in cases of optimal debulking [5,6]. Accurate
imaging helps guide the surgeon to areas of disease that
may be difficult to identify surgically. Relative criteria for
non-optimally resectable disease have been developed [7].
They include lymph node enlargement above the renal
hilum, presence of abdominal wall invasion, parenchymal
liver and subcapsular liver metastases, peritoneal implants
of >2 cm along the diaphragm, lesser sac, porta hepatis,
intersegmental fissure, gall bladder fossa, gastrosplenic,
gastrohepatic ligament and small bowel mesentery. How-
ever, it is important to realize that these criteria may vary
and will depend on the aggressiveness of the surgical pro-
cedure and on the performance status of the patient.
Therefore, they should only be used as a basis for a multi-
disciplinary consensus. It is important to note that upper
abdominal disease and pleural metastases can be surgically
resected, but this requires careful planning as it involves a
team of surgeons (e.g. liver surgeons for hepatic resection).
There has been a growing awareness of the potential of
diffusion weighted magnetic resonance imaging (DW-
MRI) in improving the mapping of the extent of ovarian
cancer [8,9]. There is also growing evidence that FDG-
PET/CT may play a role in pre-operative staging of
patients with advance ovarian cancer [10].
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